Topics
Symposia
- PSL (Low-dose Testing) & MMF, HCQ
- Sparsentan/Atrasentan/Zibasentan & SGLT2i
- Mucosal targeting therapy
- B cell targeting therapy (Anti-APRIL mAb, Atacicept, CD138)
- Complement (FB/C5/C3/C5a/MASP2)
- Panel Discussion: “How do we use all these new drugs, alone or in combination?”
CME Workshop
- Clinical epidemiology
- Genetics
- Pathogenesis NALT and GALT
- Pathology
- Treatment